Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator ...
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share ...
While the top- and bottom-line numbers for Labcorp (LH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare ...
Labcorp delivered mixed third-quarter results, with higher sales and raised profit | Labcorp reported solid third-quarter ...
Guidance Updates -- Full-year 2025 revenue growth guidance was narrowed to 7.4%-8%, with Adjusted EPS guidance was set at $16 ...
Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. The diagnostic testing company cut its revenue ...
The medical laboratory operator posted revenue of $3.56 billion in the period, which matched Street forecasts. Labcorp expects full-year earnings in the range of $16.15 to $16.50 per share.
Investing.com - Labcorp Holdings (NYSE: LH) reported third quarter EPS of $4.18, $0.05 better than the analyst estimate of $4.13. Revenue for the quarter came in at $3.56B versus the consensus ...
Zacks Investment Research on MSN
Here's Why Labcorp Holdings (LH) is a Strong Growth Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...
Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion ...
Labcorp raised the midpoint of its full-year adjusted EPS guidance by $0.05 to a range of $16.15 to $16.50, compared to the analyst consensus of $16.30. The company slightly lowered its revenue growth ...
According to Mordor Intelligence, the global clinical trials market is valued at USD 90.1 billion in 2025 and is projected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results